DailyIQ
Last updated2 minutes ago

CL·Colgate-Palmolive Company

$87.45
-0.28 (-0.32%)
Market Closed (Overnight)$87.47+0.02 (+0.02%)
High
$87.84
Open
$87.11
Market Cap
69.66B
52W High
$99.33
Low
$86.79
P. Close
$87.45
P/E
34.20
52W Low
$74.26
Fwd P/E
21.32
DailyIQ Est.
$100.20
Inst. Ownership
36.3%
Short Interest
2.16%
Days to Cover
4.2
Technical Score (1D)
18
SELL
News Sentiment
56
BULLISH
Colgate‑Palmolive’s board just reaffirmed its quarterly cash dividend at $0.53 per share, a move that extends the company’s uninterrupted payout history dating back to 1895. The dividend declaration coincides with a renewed emphasis on premium toothpaste products and a boost in advertising spend in North America, signaling management’s confidence in the firm’s cash‑generation capacity and a strategic push to capture higher‑margin segments. Because the dividend is funded by earnings and free cash flow, the payout remains sustainable for the near term, but the higher payout ratio relative to peers warrants close monitoring of future cash‑flow statements. The ad‑spend increase and price adjustments in the North American market are intended to revive demand after a weak second‑quarter performance; the effectiveness of this strategy will be reflected in the next earnings release. In the next 1–10 trading days, investors should watch for any early indications of sales lift or margin pressure that could influence the company’s guidance on dividend policy. A positive response to the premium push could reinforce the dividend’s stability, while a muted reaction might prompt a reassessment of the payout ratio. Additionally, keep an eye on the record and payment dates—October 20 and November 13, 2026—since any delay or change could affect short‑term cash‑flow expectations. Finally, monitor the company’s earnings guidance for any hints of adjustments to the dividend or capital‑allocation strategy, as that will be the most direct indicator of whether the current dividend stance will persist.
Earnings Summary
Colgate‑Palmolive, a global consumer goods company, focuses on Oral, Personal and Home Care and Pet Nutrition segments, distributing well‑known brands such as Colgate and Hill’s Science Diet across retail and veterinary channels. In the most recent two quarters with complete data—Q4 2025 and Q1 2026—the company posted EPS of $0.95 and $0.97, both beating estimates of $0.9395 and $0.9566, respectively, while revenue rose from $5.23 billion to $5.32 billion, an 8.4% increase versus the prior quarter’s $5.11 billion. Compared to the preceding two quarters (Q2 2025 and Q3 2025), EPS grew from $0.92 and $0.91 to $0.95 and $0.97, and revenue climbed from $5.11 billion and $5.13 billion to $5.23 billion and $5.32 billion, indicating a steady acceleration in top‑line growth and consistent earnings beats. Historically, the firm has maintained a positive YoY revenue trajectory, with Q4 2025 revenue up 5.9% over Q4 2024 and Q1 2026 up 8.4% over Q1 2025, while EPS has risen 4.4% and 6.6% YoY, respectively, underscoring disciplined profitability. Recent insider activity—an 8‑hour share sale by insiders juxtaposed with a large option exercise by Chairman Noel Wallace—signals mixed sentiment; the company also reported modest revenue gains offset by weaker margins, raising concerns about pricing power and cost efficiency. Investors should watch for guidance on margin targets and pricing strategy in the upcoming earnings call, monitor North American growth dynamics, and assess any strategic moves to improve cost efficiency or pricing power, as these factors will shape the next quarter’s performance.

EPS

EstBeatMiss
$0.87$0.91$0.94$0.97$1.01Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.93 - -
Q2'26$0.98$0.99+1.5%
Q1'26$0.96$0.97+1.4%
Q4'25$0.94$0.95+1.1%
Q3'25$0.89$0.91+2.4%
Q2'25$0.89$0.92+2.8%

Revenue

EstBeatMiss
$5.0B$5.2B$5.3B$5.4B$5.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$5.5B - -
Q2'26$5.5B$5.4B-2.9%
Q1'26$5.3B$5.3B-0.2%
Q4'25$5.3B$5.2B-0.8%
Q3'25 - $5.1B -
Q2'25 - $5.1B -

Market Data

CL Stock Snapshot

SELL18/100
$87.47+$0.02 (0.0%)
Market cap
69.66B
P/E ratio
34.2
Day range
$86.79 – $87.84
News sentiment
56/100 · Neutral
Analyst target
$98.95 (+13.1%)
Consensus
Buy · 32 analysts
52-week range+17.8% off low · -11.9% from high
$74.26$99.33
Price $87.47 DailyIQ Est. $100.20

CL is on the weaker side of its setup, with little confirmation for a reversal yet. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into CL?

CHEAP

At today's price, Colgate-Palmolive Company needs to grow free cash flow about -3.3% a year for the next 10 years to justify its valuation at a 6.24% cost of capital. Over its actual history it has compounded free cash flow at 2.5% a year, so the market is asking for 5.8 percentage points below its own delivered rate. On that basis CL looks priced below what its own growth record supports.

Implied FCF growth
-3.3%
Historical FCF CAGR
2.5%
Growth gap
-5.8 pts
Verdict
CHEAP
Discount rate (WACC)
6.24%
Beta
0.35

Behaviour On Record

What CL's own history says about today's numbers

Realized volatility (21d)
15.1% 43rd pct
Below its peak
-19.6%
vs 200-day average
-0.6%
Up days (1y)
51%

Colgate-Palmolive Company is currently running 15.1% annualised volatility over the last 21 sessions. Measured against CL's own 13 years of daily returns rather than a market-wide average, that is the 43rd percentile close to its own typical level, against a typical reading of 16.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CL is trading -19.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -15.8%, and the deepest was -25.3% in 2018. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -0.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 41st percentile close to the gap it normally carries. Over the past year CL closed higher on 51% of sessions, and it is currently 1 session into a falling streak.

On September specifically: over 13 years of records, CL finished the month higher 4 of 13 times, with a median return of -1.4% and an average of -1.8%. Its strongest month historically has been November at +2.4% on average, its weakest September at -1.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CL has opened more than 2% away from the prior close in 27 of 3,268 sessions (0.8% of the time), with the largest gaps running +4.7% and -6.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, CL moved an average of 1.9% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.8% and a largest of +2.9%.

All figures computed from 3,269 daily closes between 2013-09-19 and 2026-09-18, split-adjusted, recomputed daily. Percentiles are against CL's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CL's sector?

Colgate-Palmolive Company sits in the Consumer Staples sector, currently ranked 6th of 11 GICS sectors by relative-strength rotation score (improving).

Sector rank
#6 of 11
Sector state
Improving
Sector rotation score
60

Options Market

What is the options market pricing for CL?

CallsPuts

For Colgate-Palmolive Company's nearest expiry (2026-09-25, 6 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.31), with at-the-money implied volatility around 22.6%. The options market is pricing roughly a ±3.4% move by that expiry — a range of about $84.82–$90.78.

Put/call ratio (2026-09-25)
0.31
ATM implied volatility
22.6%
Total open interest
1,021
Expected move by 2026-09-25
±3.4% ($84.82–$90.78)

Analyst Rating Changes

Are analysts turning bullish or bearish on CL?

RBC Capital most recently reiterated its rating on Colgate-Palmolive Company to Outperform on Sep 8, 2026 with a price target of $104. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
RBC CapitalOutperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 8, 2026RBC CapitalReiteratedOutperform$104
Aug 3, 2026UBSMaintainedBuy$106 → $109
Aug 3, 2026TD CowenMaintainedHold$85 → $90
Aug 3, 2026JP MorganMaintainedOverweight$104 → $103
Aug 3, 2026RBC CapitalMaintainedOutperform$102 → $104
Aug 3, 2026Evercore ISI GroupMaintainedOutperform$100 → $101
Jul 21, 2026BarclaysMaintainedEqual-Weight$80 → $87
Jul 16, 2026JP MorganMaintainedOverweight$96 → $104
Jul 16, 2026UBSMaintainedBuy$100 → $106
Jul 14, 2026CitigroupMaintainedBuy$105 → $110
Jul 9, 2026Piper SandlerMaintainedOverweight$92 → $96
Jul 8, 2026Wells FargoMaintainedEqual-Weight$92 → $95

CL Competitive Positioning

Colgate-Palmolive Company (CL) is tracked alongside these names in Household & Personal Products on DailyIQ — ranked by market cap, with today's move alongside.